Yuxin Liu1, Michael M Gaisa2, Xiaofei Wang3, Talia H Swartz2, Yotam Arens4, Karen A Dresser3, Carlie Sigel5, Keith Sigel4. 1. Department of Pathology, Icahn School of Medicine at Mount Sinai. 2. Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai. 3. Department of Pathology, University of Massachusetts Medical School, Worcester. 4. Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
Background: Anal high-grade squamous intraepithelial lesions (HSILs) are the precursors to anal cancer and frequently persist or recur following electrocautery ablation (EA). Impaired mucosal immunity may facilitate anal carcinogenesis. We characterized the immune microenvironment of anal HSILs in correlation with human immunodeficiency virus (HIV) serostatus and ablation outcomes. Methods: Using immunohistochemistry, mucosa-infiltrating CD4+ and CD8+ lymphocytes were quantified in HSILs and benign mucosa from 70 HIV+ and 45 HIV- patients. Clinicopathological parameters were compared. Results: Anal HSILs harbored more T lymphocytes than benign mucosa regardless of HIV status (P ≤ .03). Total T lymphocyte count and CD8+ subset were significantly higher in HIV+ HSILs versus HIV- HSILs (median cell count, 71 vs 47; 47 vs 22/high power field [HPF]; P < .001), whereas the CD4+ subset was comparable between groups (median, 24 vs. 25; P = .40). Post EA, HSILs persisted in 41% of HIV+ and 19% of HIV- patients (P = .04). Unadjusted analysis showed trends toward EA failures associated with HIV seropositivity (incidence rate ratio [IRR], 2.0; 95% CI, .8-4.9) and increased CD8+ cells (IRR, 2.3; 95% CI, .9-5.3). Conclusions: Human immunodeficiency virus is associated with alterations of the immune microenvironment of anal HSILs manifested by increased local lymphocytic infiltrates, predominately CD8+. Human immunodeficiency virus seropositivity and excess mucosa-infiltrating CD8+ cells may be associated with ablation resistance.
Background: Anal high-grade squamous intraepithelial lesions (HSILs) are the precursors to anal cancer and frequently persist or recur following electrocautery ablation (EA). Impaired mucosal immunity may facilitate anal carcinogenesis. We characterized the immune microenvironment of anal HSILs in correlation with human immunodeficiency virus (HIV) serostatus and ablation outcomes. Methods: Using immunohistochemistry, mucosa-infiltrating CD4+ and CD8+ lymphocytes were quantified in HSILs and benign mucosa from 70 HIV+ and 45 HIV- patients. Clinicopathological parameters were compared. Results: Anal HSILs harbored more T lymphocytes than benign mucosa regardless of HIV status (P ≤ .03). Total T lymphocyte count and CD8+ subset were significantly higher in HIV+ HSILs versus HIV- HSILs (median cell count, 71 vs 47; 47 vs 22/high power field [HPF]; P < .001), whereas the CD4+ subset was comparable between groups (median, 24 vs. 25; P = .40). Post EA, HSILs persisted in 41% of HIV+ and 19% of HIV- patients (P = .04). Unadjusted analysis showed trends toward EA failures associated with HIV seropositivity (incidence rate ratio [IRR], 2.0; 95% CI, .8-4.9) and increased CD8+ cells (IRR, 2.3; 95% CI, .9-5.3). Conclusions: Human immunodeficiency virus is associated with alterations of the immune microenvironment of anal HSILs manifested by increased local lymphocytic infiltrates, predominately CD8+. Human immunodeficiency virus seropositivity and excess mucosa-infiltrating CD8+ cells may be associated with ablation resistance.
Authors: Adriana Gonçalves Daumas Pinheiro Guimarães; Roberto Moreira da Silva Junior; Oscar Tadeu Ferreira da Costa; Ivan Tramujas da Costa e Silva; Felicidad Santos Gimenez; José Ribamar de Araujo; Rosilene Viana de Andrade; Erico Jander da Silva Lopes; Jacqueline Pereira Pinheiro; Junia Raquel D Ferreira; Adriana Malheiro; Luiz Carlos de Lima Ferreira Journal: Acta Cir Bras Date: 2011-12 Impact factor: 1.388
Authors: Elizabeth A Stier; Stephen E Goldstone; J Michael Berry; Lori A Panther; Naomi Jay; Susan E Krown; Jeannette Lee; Joel M Palefsky Journal: J Acquir Immune Defic Syndr Date: 2008-01-01 Impact factor: 3.731
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Sergio Serrano-Villar; Talia Sainz; Sulggi A Lee; Peter W Hunt; Elizabeth Sinclair; Barbara L Shacklett; April L Ferre; Timothy L Hayes; Ma Somsouk; Priscilla Y Hsue; Mark L Van Natta; Curtis L Meinert; Michael M Lederman; Hiroyu Hatano; Vivek Jain; Yong Huang; Frederick M Hecht; Jeffrey N Martin; Joseph M McCune; Santiago Moreno; Steven G Deeks Journal: PLoS Pathog Date: 2014-05-15 Impact factor: 6.823
Authors: Jessica L Castilho; Aihua Bian; Cathy A Jenkins; Bryan E Shepherd; Keith Sigel; M John Gill; Mari M Kitahata; Michael J Silverberg; Angel M Mayor; Sally B Coburn; Dorothy Wiley; Chad J Achenbach; Vincent C Marconi; Ronald J Bosch; Michael A Horberg; Charles S Rabkin; Sonia Napravnik; Richard M Novak; W Christopher Mathews; Jennifer E Thorne; Jing Sun; Keri N Althoff; Richard D Moore; Timothy R Sterling; Staci L Sudenga Journal: J Natl Cancer Inst Date: 2022-06-13 Impact factor: 11.816
Authors: Yuxin Liu; W Glenn McCluggage; Teresa M Darragh; Wenxin Zheng; Jennifer M Roberts; Kay J Park; Pei Hui; Morgan Blakely; Keith Sigel; Michael M Gaisa Journal: Am J Clin Pathol Date: 2021-05-18 Impact factor: 2.493